# Protalix BioTherapeutics, Inc.: Form 8-K, filed Aug 26, 2021

- Company: [Protalix BioTherapeutics, Inc.](/companies/plx.md) (CIK 1006281)
- Form: 8-K
- Filed: 2021-08-26
- Accepted by EDGAR: Aug 26, 2021, 07:16 ET
- Period: 2021-08-24
- Accession: 0001558370-21-012078
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824x8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.03: New direct financial obligation
- Item 3.02: Unregistered sale of equity
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824x8k.htm

Filed Aug 26, 2021.
Source: SEC EDGAR, the filing index for accession 0001558370-21-012078. Last ingested by Listed: Nov 10, 2026, 16:48 ET. No prices; not investment advice.
